Press coverage about Enzymotec (NASDAQ:ENZY) has trended somewhat positive recently, Accern Sentiment reports. The stock was last seen 11.24% higher, reaching at $9.4 on August 1, 2017.
Following U.S. election volatility some analysts have updated their recommended target prices on shares of Enzymotec Ltd. (NASDAQ:ENZY). Therefore 67% are positive.
Enzymotec Ltd. has a 50 day moving average of 7.76 and a 200 day moving average of 8.35. It has underperformed by 6.69% the S&P500.
At the end of Mar reporting period, 5 institutional holders increased their position in Enzymotec Ltd. (NASDAQ:ENZY) by some 9,635 shares, 15 decreased positions by 384,888 and 10 held positions by 6,012,915. The Business's technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.06 by $0.03.
On August 13 the company was upgraded to "Outperform" from "Market Perform" in a statement from Wells Fargo.
November 23 investment analysts at Jefferies maintained a company rating of "Hold" and moved down the price target to $7.00 from $11.00. The firm's market cap is $215.68 million. The Firm operates in two divisions: Nutrition segment and VAYA Pharma segment.
Timucuan Asset Management Inc Fl holds 9.72% of its portfolio in Hexcel Corporation for 2.14 million shares. Broad Run Investment Management Llc owns 2.86 million shares or 6.07% of their United States portfolio. Moreover, Ingalls & Snyder Llc has 4.03% invested in the company for 1.44 million shares. The stock's market capitalization is 184.34M.
Enzymotec (NASDAQ:ENZY) last issued its quarterly earnings data on Wednesday, May 17th. Renaissance Technologies LLC now owns 290,000 shares of the biotechnology company's stock valued at $1,900,000 after buying an additional 31,700 shares during the last quarter. Also, there are 0 buy, 1 sell and 0 strong sell ratings, collectively assigning a 3.33 average brokerage recommendation.
Receive Enzymotec Ltd. News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. with MarketBeat.com's FREE daily email newsletter.